Researchers from the Dragon Trials Collaborative, an international consortium led by MUMC+, have studied a new treatment method that would allow more people with colon cancer that has spread to the liver to undergo surgery. They are now investigating whether this method can also be applied to people with a primary liver tumor.
When liver cancer is surgically removed, at least 30% of the remaining liver must remain. It is possible for this remaining liver to grow before the operation. The research group has developed a new method for this purpose, and preliminary results show that 90% of patients with initially small residual liver size can eventually undergo the operation.
The current study focuses only on patients with colon cancer that has spread to the liver. The researchers will now also apply this method to patients with primary liver tumors in the bile ducts or in the liver tissue itself.
In collaboration with about 60 hospitals in different countries, they will treat 364 patients in the Dragon Primary Liver Cancer (PLC) trial, half of whom will use the new method. Researchers then collect data on the results of treatments and participants are followed for 5 years to gain insight into potential disease recurrence and survival. The researchers received a grant from the Dutch Cancer Society to expand the research.
“Total coffee specialist. Hardcore reader. Incurable music scholar. Web guru. Freelance troublemaker. Problem solver. Travel trailblazer.”